Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

Background Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael C Jensen, Venu G Pillarisetty, Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Richard G Ellenbogen, Jean S Campbell, Robert H Pierce, Eric C Holland, Courtney A Crane
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001356.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001356.full

Similar Items